RxDoctor Payments Data

Chad Carr, MD

Cardiovascular Disease · Portland, ORNPI 1912119603

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,017 of the $3,271 with a category attached, or 61.6%. Abbott accounts for 66.2% of it on its own, with 7 other manufacturers making up the rest.

$3,271in general payments, 2019–2025

Across 32 payments — averaging $102.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$331
  • Abiomed$272
  • Medtronic$264
  • Boston Scientific$194
  • Shockwave Medical, Inc$18
  • plus $27 from 2 others

What the payments were for

  • Travel & lodging$2,01762%
  • Food & beverage$1,25538%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,271 in reported general payments places this provider in the 75th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$67,736
Medicare patients
664
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban473$591,761
EntrestoSacubitril/Valsartan136$154,701
JardianceEmpagliflozin101$120,664
XareltoRivaroxaban75$85,582
Repatha SureclickEvolocumab43$43,444
FarxigaDapagliflozin Propanediol24$39,807
Praluent PenAlirocumab18$14,513
Metoprolol Succinate517$7,005
Atorvastatin Calcium465$4,968
Rosuvastatin Calcium212$3,624
Amiodarone Hcl160$2,822
Torsemide73$2,758
Losartan Potassium234$2,750
Carvedilol337$2,654
Ezetimibe86$2,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$13$120,664101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →